This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zoldhelyi, P. Articles by Chesebro, J. H. Search for Related Content PubMed PubMed Citation Articles by Zoldhelyi, P. Articles by Chesebro, J. H.

Circulation, Vol 90, 2671-2678, Copyright © 1994 by American Heart Association

ARTICLES

Persistent thrombin generation in humans during specific thrombin inhibition with hirudin

P Zoldhelyi, J Bichler, WG Owen, DE Grill, V Fuster, JS Mruk and JH Chesebro
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn.

BACKGROUND: The degree to which antithrombotic drugs suppress thrombin generation is unknown. Because hirudin, unlike antithrombin III, binds intravascular thrombin rapidly and selectively to yield a circulating inactive complex of 3- to 4-hour half-life, we used intravenous hirudin in humans to investigate the course of thrombin generation during and early after anticoagulation with this potent, direct antithrombin. METHODS AND RESULTS: Intravascular thrombin was measured with an ELISA for the thrombin-hirudin complex formed during and for 18 hours after stopping a 6-hour infusion of hirudin at 0.1, 0.2, and 0.3 mg.kg-1.h-1 in three groups of six patients each. With free hirudin in 20- to 10,000-fold molar excess of thrombin and peak activated partial thromboplastin times of 2.3 to 3.0 times baseline, mean plasma thrombin- hirudin complex increased from 794 +/- 85 pg/mL (mean +/- SEM) 15 minutes after the start of the infusion to 1617 +/- 151 pg/mL at 6 hours of infusion to 2667 +/- 654 pg/mL at 24 hours. During the 24-hour observation period, plasma concentration of fragment 1.2 (the peptide released during conversion of prothrombin to thrombin) never fell below baseline but rather increased transiently during the hirudin infusion. Plasma concentrations of thrombin-antithrombin III complex (in ng/mL) decreased from 4.34 +/- 0.40 at baseline to 1.64 +/- 0.13 at 6 hours (P < .001) and gradually increased after stopping the infusion to 5.7 +/- 0.87 at 24 hours (nonsignificant compared with baseline). CONCLUSIONS: Measurement of thrombin-hirudin complex may be used as a marker of thrombin generation in humans. Persistent accumulation of thrombin- hirudin complex and generation of fragment 1.2 during and after completion of potent anticoagulation with hirudin suggest thrombin generation is not blocked by high-affinity thrombin inhibition. The persistent formation of thrombin during declining plasma levels of hirudin may contribute to the pathogenesis of rethrombosis early after antithrombin therapy or during inadequate anticoagulation.

This article has been cited by other articles:

				H. L. Messmore Jr, J. Fareed, J. M. Walenga, and R. L. Bick Argatroban and Lepirudin: Clinical Trials to Clinical Practice Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 367 - 369. [PDF]

				F. D. Rubens, G. Lavalee, M. A. Ruel, T. Mesana, and M. Bourke Delayed Thrombin Generation With Hirudin Anticoagulation During Prolonged Cardiopulmonary Bypass Ann. Thorac. Surg., January 1, 2005; 79(1): 334 - 336. [Abstract] [Full Text] [PDF]

				M. Jormalainen, A. E. Vento, U. Wartiovaara-Kautto, R. Suojaranta-Ylinen, O. J. Ramo, and J. Petaja Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 189 - 196. [Abstract] [Full Text] [PDF]

				C. K. Derian, B. P. Damiano, M. F. Addo, A. L. Darrow, M. R. D'Andrea, M. Nedelman, H.-C. Zhang, B. E. Maryanoff, and P. Andrade-Gordon Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 855 - 861. [Abstract] [Full Text] [PDF]

				D. R. Abendschein, P. K. Baum, P. Verhallen, P. R. Eisenberg, M. E. Sullivan, and D. R. Light A Novel Synthetic Inhibitor of Factor Xa Decreases Early Reocclusion and Improves 24-h Patency after Coronary Fibrinolysis in Dogs J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 567 - 572. [Abstract] [Full Text]

				M.D Flather, J.I Weitz, S Yusuf, J Pogue, B Sussex, J Campeau, J Gill, R Schuld, C.D Joyner, A.L Morris, et al. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial Eur. Heart J., September 1, 2000; 21(17): 1473 - 1481. [Abstract] [PDF]

				P. A. Merlini, D. Ardissino, R. D. Rosenberg, E. Colombi, P. Agricola, L. Oltrona, F. Ottani, M. Galvani, K. A. Bauer, B. Bottasso, et al. In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2162 - 2166. [Abstract] [Full Text] [PDF]

				T. Pernerstorfer, U. Hollenstein, J.-B. Hansen, P. Stohlawetz, H.-G. Eichler, S. Handler, W. Speiser, and B. Jilma Lepirudin blunts endotoxin-induced coagulation activation Blood, March 1, 2000; 95(5): 1729 - 1734. [Abstract] [Full Text] [PDF]

				R. C. Becker, F. A. Spencer, Y. Li, S. P. Ball, Y. Ma, T. Hurley, and J. Hebert Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1020 - 1027. [Abstract] [Full Text] [PDF]

				R. Linder, J. Oldgren, N. Egberg, L. Grip, G. Larson, A. Siegbahn, and L. Wallentin The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease Eur. Heart J., April 1, 1999; 20(7): 506 - 518. [Abstract] [PDF]

				R. Gallo, A. Padurean, V. Toschi, J. Bichler, J. T. Fallon, J. H. Chesebro, V. Fuster, and J. J. Badimon Prolonged Thrombin Inhibition Reduces Restenosis After Balloon Angioplasty in Porcine Coronary Arteries Circulation, February 17, 1998; 97(6): 581 - 588. [Abstract] [Full Text] [PDF]

				G. Ghigliotti, A. R. Waissbluth, C. Speidel, D. R. Abendschein, and P. R. Eisenberg Prolonged Activation of Prothrombin on the Vascular Wall After Arterial Injury Arterioscler. Thromb. Vasc. Biol., February 1, 1998; 18(2): 250 - 257. [Abstract] [Full Text] [PDF]

				J. H. Chesebro Direct Thrombin Inhibition Superior to Heparin During and After Thrombolysis : Dose, Duration, and Drug Circulation, October 7, 1997; 96(7): 2118 - 2120. [Full Text]

				P. A. Merlini, D. Ardissino, K. A. Bauer, L. Oltrona, A. Pezzano, B. Bottasso, R. D. Rosenberg, and P. M. Mannucci Persistent Thrombin Generation During Heparin Therapy in Patients With Acute Coronary Syndromes Arterioscler. Thromb. Vasc. Biol., July 1, 1997; 17(7): 1325 - 1330. [Abstract] [Full Text]

				R. P. Schwarz JR, J.-C. P. Becker, R. L. Brooks, M. J. Hursting, J. L. Joffrion, G. D. Knappenberger, T. P. Kogan, P. W. Kogan, and A. A. McKinney State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor Clinical and Applied Thrombosis/Hemostasis, January 1, 1997; 3(1): 1 - 15. [Abstract] [PDF]

				A. K. Rao, L. Sun, J. H. Chesebro, V. Fuster, R. A. Harrington, D. Schwartz, P. Gallo, D. Matos, and E. J. Topol Distinct Effects of Recombinant Desulfatohirudin (Revasc) and Heparin on Plasma Levels of Fibrinopeptide A and Prothrombin Fragment F1.2 in Unstable Angina: A Multicenter Trial Circulation, November 15, 1996; 94(10): 2389 - 2395. [Abstract] [Full Text]

				C. R. McKenzie, D. R. Abendschein, and P. R. Eisenberg Sustained Inhibition of Whole-Blood Clot Procoagulant Activity by Inhibition of Thrombus-Associated Factor Xa Arterioscler. Thromb. Vasc. Biol., October 1, 1996; 16(10): 1285 - 1291. [Abstract] [Full Text]

				P. W. Serruys, J.-P. R. Herrman, R. Simon, W. Rutsch, C. Bode, G.-J. Laarman, R. van Dijk, A. A. van den Bos, V. A.W.M. Umans, K. A.A. Fox, et al. A Comparison of Hirudin with Heparin in the Prevention of Restenosis after Coronary Angioplasty N. Engl. J. Med., September 21, 1995; 333(12): 757 - 764. [Abstract] [Full Text] [PDF]